strongly point to a key regulatory role of HMGB1 in PMN recruitment to inflammatory tissues. The A box component could potentially serve to inhibit inappropriate PMN recruitment during chronic inflammatory disorders associated with excessive HMGB1 release.
damage. Negative signals present at inflammatory sites prevent PMN recruitment, dampen PMN responsiveness and counterbalance or terminate the inflammatory response. This anti-inflammatory program is characterized by cessation of PMN infiltration.
High-mobility group box 1 (HMGB1) is a nuclear protein loosely bound to DNA, which stabilizes nucleosome formation and regulates transcription [3] . HMGB1 is found in all mammalian tissues and is highly conserved among species. HMGB1 consists of a single polypeptide chain of 215 amino acids organized into two DNA-binding regions (the A and B box) and a C-terminal acidic tail. HMGB1 can be actively secreted into the extracellular space by activated macrophages, natural killer cells and mature dendritic cells, a process that may require HMGB1 acetylation in the nucleus. HMGB1 is passively released by necrotic but not apoptotic cells, and is thus a key signal of tissue damage. Extracellular HMGB1 may interact with Toll-like receptor (TLR) 2 and TLR4, and/or receptor for advanced glycation end products (RAGE). As a danger signal, HMGB1 would be expected to trigger inflammation, but recent reports indicate that pure recombinant HMGB1 has no pro-inflammatory activity and only acts as a chemoattractant and a mitogen. HMGB1 acquires pro-inflammatory activity after binding to proinflammatory mediators such as IL-1 ␤ , LPS and ssDNA [4] [5] [6] . Structure-function studies have shown that the active cytokine domain of HMGB1 is located in the DNAbinding B box, whereas the A box competes with HMGB1 for binding sites on the surface of activated macrophages and attenuates the biological function of full-length HMGB1; thus, the recombinant A box specifically antagonizes HMGB1 [3, 7] .
Although HMGB1 has been reported to stimulate the motility of various cell types such as fibroblasts, dendritic cells, macrophages, smooth muscle cells and tumor cells [for review, see 3 ] , it is unclear whether this includes human PMN. Orlova et al. [8] recently reported that HMGB1 induces a RAGE-mediated increase in PMN migration. However, this latter study used PMN isolated from their blood environment by procedures which may differently modulate cell surface receptor expression and thereby alter cell responses [9] .
The aim of the present study was to assess the effect of HMGB1 on PMN migration in whole-blood conditions in order to avoid artifactual activation related to isolation procedures and to more closely reproduce physiological conditions. We also analyzed the respective roles of the A and B box on chemotaxis, cytoskeleton rearrangement and PMN activation status. Finally, we examined the possible involvement of RAGE, TLR2 and TLR4 in the modulation of PMN migration by HMGB1, and investigated relevant transduction pathways.
Materials and Methods

Reagents
The reagents and sources were as follows: fMLP and L-␣ lysophosphatidylcholine (Sigma-Aldrich); cycloheximide, SB203580, PD98059 and wortmannin (Calbiochem); recombinant human IL-8 and anti-RAGE monoclonal antibody (R&D Systems); ultrapurified LPS from Escherichia coli serotype R515 (Invivogen); PEconjugated anti-CD11b antibody (Dakopatts); 7-aminoactinomycin D (7-AAD), allophycocyanin-conjugated (APC) anti-CD15 antibody, PE-conjugated anti-phosphorylated p38MAPK and ERK1/2 antibodies, purified anti-phospho Akt (S472/S473) antibody, purified anti-L -selectin antibody, and cytometric bead array (CBA) kit (BD Pharmingen); FITC goat anti-mouse antibody (Nordic Immunology); FITC goat anti-rabbit polyclonal antibodies (Cell Signaling Technology); anti-human TLR2 and TLR4 antibodies (eBiosciences); unlabeled phalloidin, Alexa Fluor 488-phalloidin and SYTO16 (Invitrogen); hydroethidine (HE) (Fluka, Buchs, Switzerland); Transwell plates (Corning Costar).
Purification of Recombinant Human HMGB1 and HMGB1 Domains A and B
Recombinant human HMGB1, HMGB1 domain A (residues 1-87) and HMGB1 domain B (residues 85-180) were produced from Escherichia coli strain BL21(DE3) pLysS transformed with pEt15b-6His-HMGB1 full-length, pEt15b-6His-A Box and pEt15b-6His-B Box as previously described [10, 11] . The expression vector encoded human HMGB1 protein, domain A and domain B fused to a polyhistidine tag at their N termini. (His) 6 -fusion proteins of full-length HMGB1 and of domains A and B were extracted in denaturing conditions, then renaturated and affinity-purified on Ni-NTA spin columns as recommended in the Qiagen instruction manual. Contaminating endotoxin was removed with Triton X-114 [10] and full-length HMGB1, domains A and B were tested for endotoxin contamination using the Limulus amebocyte assay. In order to rule out possible denaturation of HMGB1 during protein production, the activity of HMGB1 was assessed in terms of the capacity of HMGB1 to bind to hemicatenated DNA [11, 12] and to stimulate migration of 3T3 mouse fibroblasts [13] .
Measurement of PMN Chemotactic Activity
Chemotaxis was measured in Transwell plates (Corning Costar) containing 3-m pore-size polyvinylpyrrolidone-free polycarbonate filters [14] . The lower well of each chamber received 600 l of HMGB1 (1-5,000 ng/ml) or advanced glycation end products (AGEs) (1-5,000 ng/ml) diluted in PBS plus 1% human serum albumin. IL-8 at 25 ng/ml and fMLP at 10 -7 M were used as positive chemoattractant controls. Spontaneous migration was measured with PBS plus 1% human serum. The upper well received 100 l of healthy donor whole blood diluted 1/10 in PBS. The chambers were incubated for 1, 3 or 5 h at 37 ° C. Samples were stained with APC-anti-CD15 for 15 min, and 450 l of lysis solution was then added. The total number of PMN added to the upper well and the number of PMN that migrated to the lower well were HMGB1 Modulates PMN Migration J Innate Immun 2012;4:41-58 43 determined by flow cytometry using TruCount tubes (BD Biosciences). In some experiments, whole-blood samples were pretreated for 5-20 min with cycloheximide (10 g/ml), blocking TLR2, TLR4 or RAGE antibodies (10 g/ml), or kinase inhibitors at optimal concentrations previously determined in whole blood (wortmannin 2,500 n M ; PD98059 50 M ; SB203580 25 M ) [15] .
In order to evaluate the effect of HMGB1 on IL-8-and fMLPinduced migration, the lower wells were pretreated with HMGB1 at various concentrations for 30 min and then with IL-8 (25 ng/ ml) or fMLP (10 -7 M ) for 180 min.
Determination of Adhesion Molecule Expression at the PMN Surface
Whole-blood samples (1 ml) were incubated at 37 ° C with PBS, TNF-␣ (100 U/ml, used as a positive control), A box (1-5,000 ng/ ml, HMGB1 equivalent) or B box (1-5,000 ng/ml, HMGB1 equivalent) for 1 h. In order to evaluate the effect of A or B box on IL-8-and fMLP-induced changes in adhesion molecule expression, the samples were pretreated with A or B box at various concentrations for 15 min and then with IL-8 (25 ng/ml) or fMLP (10 -7 M ) for 45 or 5 min, respectively. Samples (100 l) were stained at 4 ° C for 30 min with PE-anti-human CD11b or purified anti-L -selectin antibodies. To study L -selectin expression, samples were then washed with ice-cold PBS and incubated at 4 ° C for 30 min with FITC-goat anti-mouse antibody. Erythrocytes were lysed with FACS lysing solution (BD Biosciences) and white blood cells were resuspended in 1% paraformaldehyde-PBS and analyzed by flow cytometry. Nonspecific antibody binding was determined on cells incubated with the same concentration of an irrelevant antibody of the same isotype.
F-Actin Assay
Whole-blood samples were either kept on ice or incubated PBS, A box (1-5,000 ng/ml, HMGB1 equivalent) or B box (1-5,000 ng/ml, HMGB1 equivalent) for 1 h. In order to evaluate the effect of A or B box on IL-8-and fMLP-induced changes in actin polymerization, the samples were pretreated with A or B box for 1 h, and then with PBS, fMLP (10 -7 mol/l) or IL-8 (25 ng/ml) for 2 min at 37 ° C. Cells obtained after red cell lysis were fixed with 1% paraformaldehyde-PBS, and F-actin was measured by flow cytometry as previously described [16] . One hundred microliters of cell suspension was incubated for 30 min at 0 ° C in 100 l of 8% paraformaldehyde and 200 l/ml L -␣ lysophosphatidyl-choline in PBS alone or supplemented with 1 mmol/l unlabeled phalloidin to measure nonspecific binding of Alexa Fluor 488-phalloidin. Alexa Fluor 488-phallodin (20 M ) was then added to the suspension and incubation was continued for 30 min at 0 ° C. After one wash in PBS, the cells were resuspended in 1% paraformaldehyde-PBS.
Measurement of PMN Oxidative Burst
Superoxide anion O 2 -ؒ production was measured with a flowcytometric assay derived from the HE oxidation technique [15] : whole-blood samples (500 l) were loaded for 15 min with HE (1,500 ng/ml) at 37 ° C and then incubated with PBS, TNF-␣ (100 U/ml, used as a positive control), A box (1-5,000 ng/ml, HMGB1 equivalent) or B box (1-5,000 ng/ml, HMGB1 equivalent) for 1 h; samples were then treated with PBS or 10 -6 M fMLP for 5 min. Red cells were lysed as described above and white cells were resuspended in 1% paraformaldehyde-PBS.
Measurement of PMN Apoptosis
Apoptosis of PMN in whole blood was quantified by using SYTO16 [17] and a vital dye (7-AAD) [15] . Following initiation of the apoptosis cascade, cells loaded with SYTO16 exhibit a characteristic initial reduction in fluorescence signal intensity which precedes plasma membrane rupture. As cell death processes advance, a further loss of SYTO16 fluorescence coincides with the loss of plasma membrane integrity [17] . Samples were incubated in 24-well tissue culture plates at 37 ° C with 5% CO 2 for 3 and 24 h with PBS or HMGB1 (1-5,000 ng/ml). Cycloheximide (10 g/ml) and LPS (10 ng/ml) were used as pro-and antiapoptotic controls, respectively [15] . Samples (100 l) were then washed twice in PBS, incubated on ice with APC-anti-CD15 for 15 min, and then with SYTO16 (20 n M ) for 15 min. After dilution in PBS (500 l), the samples were incubated with 7-AAD at room temperature for 15 min and analyzed immediately by flow cytometry.
Study of Intracellular Phospho-Akt, Phospho-p38MAPK and Phospho-ERK1/2
After incubation of whole-blood samples with PBS, A box (1-5,000 ng/ml, HMGB1 equivalent) or B box (1-5,000 ng/ml, HMGB1 equivalent) for various times at 37 ° C, leukocytes were permeabilized in 90% methanol as previously reported [15] . Cells were then stained with anti-Akt phosphospecific for 1 h at room temperature and washed once in PBS-2% HSA. Samples were then incubated for 30 min with FITC-goat anti-rabbit antibody. Phospho-p38MAPK and phospho-ERK1/2 contents were studied by staining with PE-conjugated anti-phospho-p38MAPK and antiphospho-ERK1/2 antibodies. After one wash, leukocytes were resuspended in 1% paraformaldehyde-PBS and analyzed by flow cytometry.
Cytokine Production by Blood Cells
Whole-blood PMN were cultured for 1, 3 and 24 h at 37 ° C with 5% CO 2 in 24-well tissue culture plates (Costar) in RPMI 1640 medium (Sigma-Aldrich). HMGB1 (1-5,000 ng/ml) was added to the culture medium. LPS (20 ng/ml) was used as a positive control. Supernatants were stored at -70 ° C for no longer than 15 days before assay. IL-8, IL-6, IL-1 ␤ and TNF-␣ were detected simultaneously in supernatants by using the human inflammatory cytokine CBA kit (BD Pharmingen). The CBA working range is 20-5,000 pg/ml for each cytokine.
Flow Cytometry
We used a BD Biosciences LSRII device (Immunocytometry Systems). PMN functions were analyzed with DIVA software. To measure apoptosis in whole blood, PMN were identified on the CD15/SSC dot plot, and 2 ! 10 5 events were counted per sample. In other experiments, forward and side scatter were used to identify the PMN population and to gate out other cells and debris; 10 4 events were counted per sample. Cytokine levels were analyzed with CBA software (BD Pharmingen).
Statistical Analysis
Data are reported as means 8 SEM. Comparisons were based on ANOVA and Tukey's post hoc test, using Prism 3.0 software (Graph Pad Software).
Results
HMGB1 Effects on PMN Migration Depend on the Concentration
We first investigated the effect of HMGB1 (1-5,000 ng/ ml) alone on migration of whole-blood PMN incubated for 3 h in Transwell plates. Maximal concentrations of IL-8 (25 ng/ml) and fMLP (10 -7 M ), used as positive controls, induced significant migration of PMN as compared to PBS-HSA ( fig. 1 a) . The highest concentration of HMGB1 (5,000 ng/ml) increased PMN migration to a similar extent to fMLP. Surprisingly, HMGB1 at lower concentrations (50 and 100 ng/ml) significantly decreased baseline PMN migration ( fig. 1 a) . A kinetic study showed that this inhibition was maximal after 1 h (55%), falling to 39% after 3 h and 10% after 5 h. In contrast, the increase in PMN migration induced by the highest HMGB1 concentration was significantly lower after 1 h (28%) than after 3 h (58%) ( fig. 1 b) . PMN chemotaxis towards IL-8 and fMLP was significantly reduced when the cells were preincubated with low HMGB1 concentrations (10, 50 or 100 ng/ml) for 30 min ( fig. 1 c) . In contrast, a higher HMGB1 concentration (5,000 ng/ml) enhanced PMN migration towards fMLP.
As interactions between HMGB1 and leukocyte lineages may occur in whole-blood conditions, we examined the effect of 1 h incubation with HMGB1 on isolated PMN, purified as previously reported [15] . HMGB1-induced modulations of PMN migration were similar whether migration was studied in whole blood or in purified preparations, suggesting a direct effect of HMGB1 on PMN migration. However, the effects were slightly lower with purified PMN than with whole-blood PMN: in purified preparations, HMGB1 (100 ng/ml) induced 32-38% inhibition of PMN migration and the highest HMGB1 concentration induced a 15-21% increase in PMN migration. To minimize cell activation due to isolation procedures and to better mimic physiological conditions, subsequent experiments were performed with PMN in their whole-blood environment.
HMGB1 Modulation of PMN Migration Is Not Related to Altered PMN Viability
Bloodstream PMN have a short half-life, dying physiologically by apoptosis. Apoptotic PMN are nonfunctional. We therefore investigated whether the observed changes in PMN migration were due to modulation of PMN survival. Whole-blood PMN cultured at 37 ° C died rapidly by apoptosis: about 10 and 70% of cells were SYTO low+bright after 3 and 24 h, respectively. As previously reported [15] , apoptosis was accelerated by cycloheximide (10 g/ml: 18% of cells were SYTO low+bright after 3 h) and delayed by LPS (10 ng/ml: 4% of cells were SYTO low+bright after 3 h) ( fig. 2 c) . The percentage of apoptotic cells in samples incubated with HMGB1 (1-5,000 ng/ml) for 3 h was not different from the PBS control ( fig. 2 c) . Similar results were obtained after 24 h (data not shown).
HMGB1 A and B Box Have Opposite Effects on PMN Migration
We then investigated the involvement of the A and B domains in HMGB1 modulation of PMN migration. The A box (50-1,000 ng/ml HMGB1 equivalent) significantly decreased PMN random migration ( fig. 3 a) as well as fMLP-and IL-8-induced chemotaxis ( fig. 3 c, d ). In addition, pretreatment of whole-blood samples with the A box (100 ng/ml HMGB1 equivalent) strongly accentuated the inhibition of PMN migration observed with 100 ng/ml HMGB1 ( fig. 3 g ) and totally suppressed the increase in PMN migration observed with 5,000 ng/ml HMGB1 ( fig. 3 h) . In contrast, high B box concentrations (1,000 and 5,000 ng/ml HMGB1 equivalent) significantly increased PMN migration compared to the PBS-HSA control ( fig. 3 b) , as well as fMLP-induced chemotaxis ( fig. 3 e) . Together, these data suggested that the B and A box might play key roles in the observed enhancement and inhibition, respectively, of PMN migration by HMGB1.
HMGB1 A and B Box Modulations of PMN Migration
Are Associated with Changes in F-Actin Content F-actin is important for the cytoskeleton rearrangements necessary to induce a migratory phenotype in PMN [18] . We therefore investigated whether the differential effects of the two parts of HMGB1 on PMN migration were associated with parallel changes in F-actin content. As shown in figure 4 , treatment of whole-blood samples with A box reduced actin polymerization in unstimulated PMN ( fig. 4 a) , as well as in response to fMLP ( fig. 4 c) and IL-8 ( fig. 4 d) . In contrast, high B box concentrations (1,000 and 5,000 ng/ml HMGB1 equivalent) significantly increased the PMN F-actin content ( fig. 4 b) . In addition, as observed above for PMN migration, HMGB1 B box (5,000 ng/ml) and fMLP had a synergistic effect on F-actin content ( fig. 4 e) . 
Effect of HMGB1 A and B Box on PMN Adhesion Molecule Expression and Oxidative Burst
As HMGB1 A and B box were found to modulate PMN migration, we then explored whether these two parts could also differentially affect neutrophil activation status in terms of adhesion molecule expression and ROS production. In keeping with the known role of CD11b during PMN migration [19] , we found that the A box significantly decreased CD11b expression as compared to the PBS control ( fig. 5 a) and counteracted chemoattractant-induced CD11b upregulation ( fig. 5 e, f) . In contrast, the A box did not modify L -selectin expression ( fig. 5 c) and did not reverse L -selectin shedding after PMN activation by fMLP or IL-8 (data not shown). High B box concentrations induced an increase in CD11b expression and a decrease in L -selectin expression ( fig. 5 b, d ). These mod- The lower wells were pretreated with PBS-HSA (1%) or B box (1-5,000 ng/ml, HMGB1 equivalent) for 1 h and then with fMLP (10 -7 M ) ( e ) or IL-8 (25 ng/ml) ( f ) for 30 min in Transwell plates at 37 ° C. The results are expressed as the migration rate calculated as described above. Values are means 8 SEM (n = 3, each experiment performed in triplicate). g , h A box modulates HMGB1-induced changes in PMN migration. Before being applied to the upper chambers, whole-blood samples were pretreated at room temperature for 30 min with A box (100 ng/ml, HMGB1 equivalent). The lower well of each chamber received 600 l of PBS-HSA or HMGB1 (100 ng/ml or 5,000 ng/ml) and the chambers were incubated at 37 ° C for 1 h (HMGB1 100 ng/ml) ( g ) or 3 h (HMGB1 5,000 ng/ml) ( h ). The results are expressed as the percentage inhibition or percentage increase, according to the HMGB1 concentration (100 ng/ml or 5,000 ng/ml, respectively) as described in the legend of fig. 1b . Values are means 8 SEM (n = 3, each experiment performed in triplicate). * Significantly different from sample incubated with PBS- HSA ( a , b , g , h ) , fMLP ( c , e ) or IL-8 We have previously reported that, in whole blood, a given stimulus gives rise to minimal ROS production by PMN that have not been preactivated ('primed') [16] . We therefore studied the effect of HMGB1 on the oxidative burst after PMN priming. As shown in figure 5 g and h, neither A nor B box modulated ROS production in response to fMLP.
The HMGB1-Induced Increase in PMN Migration Is Related to IL-8 Synthesis
Preincubation of whole-blood samples for 30 min with cycloheximide (10 g/ml) suppressed the HMGB1-induced increase in PMN migration but had no effect on the HMGB1-induced decrease in PMN migration observed at lower concentrations ( fig. 6 a) . In addition, incubation of whole-blood samples with HMGB1 (1,000 and 5,000 ng/ml) for 3 h significantly increased IL-8 production as compared to PBS ( fig. 6 b) , while TNF-␣ , IL-1 ␤ and IL-6 remained undetectable ( fig. 6 c) . In keeping with previous data [7] , preincubation of whole-blood samples with the A box for 15 min suppressed HMGB1-induced IL-8 production ( fig. 6 b) . HMGB1 induced significantly less IL-8 production than LPS, with levels never exceeding 6 ng/ml after 3 h of incubation ( fig. 6 b) . However, IL-8 was found to have a chemotactic effect at concentrations as low as 2.5 ng/ml ( fig. 6 d) . The HMGB1-induced increase in PMN migration was totally reversed by preincubation of whole-blood samples with an anti-IL-8 antibody ( fig. 6 e) , while an irrelevant antibody of the same isotype had no effect. These findings suggested that HMGB1-induced IL-8 production might be involved in the chemotactic effect of HMGB1 on PMN.
Transduction Pathways Involved in HMGB1-Induced Modulation of PMN Migration
We examined the possible involvement of RAGE, TLR2 and TLR4 in the differential modulation of PMN migration by HMGB1. As shown in figure 7 a, the inhibitory effect of HMGB1 100 ng/ml on PMN migration was strongly countered by cell pretreatment with anti-RAGE, while the stimulatory effect of HMGB1 5,000 ng/ ml was significantly countered by pretreatment with anti-RAGE, anti-TLR2 or anti-TLR4. We also analyzed the effect of advanced glycation end products (AGEs), reported to interact with RAGE, on PMN migration. We observed a decrease in PMN random migration in the presence of AGEs at 50 and 100 ng/ml, while higher concentrations did not have a significant chemotactic effect ( fig. 7 b) . Together, these results suggest that the decrease in PMN migration observed with low concentrations of HMGB1 is mediated by RAGE receptors, while supplementary engagement of TLR2 and TLR4 may be required for the enhancement of PMN chemotaxis observed at higher HMGB1 concentrations. In keeping with previous data [20] , preincubation of whole-blood samples with anti-RAGE, anti-TLR2 or anti-TLR4 significantly reduced HMGB1-induced IL-8 production ( fig. 6 f) .
We then investigated the possible participation of various kinases in A box-induced inhibition of PMN migration, by using pharmacological inhibitors of PI3-K (wortmannin), as well as ERK1/2 inhibitor (PD98059) and p38MAPK inhibitor (SB206580). As shown in figure 7 c, inhibition of p38MAPK and PI3-K suppressed the chemotactic effect of HMGB1 5,000 ng/ml and accentuated the inhibitory effect of HMGB1 100 ng/ml. Interestingly, HMGB1-induced inhibition of PMN migration was totally reversed in the presence of the ERK1/2 inhibitor PD98059. Moreover, incubation of whole blood with low concentrations of A box increased the phospho-ERK1/2 content ( fig. 7 d) and decreased the phospho-p38MAPK content ( fig. 7 e) . Pretreatment with the ERK1/2 inhibitor reversed the A box-induced decrease in PMN phosphop38MAPK content ( fig. 7 f) .
Discussion
Neutrophils are the first cells to be recruited to sites of infection in response to a variety of inflammatory stimuli, and they protect the host by engulfing, killing and digesting invading infectious agents. However, in case of excessive or misdirected responses, PMN may have detrimental effects that contribute to many inflammatory disorders [21] . Fine regulation of PMN recruitment is therefore necessary for optimal antibacterial defenses. We show here that the alarmin HMGB1, at concentrations of 50-100 ng/ml, inhibits both baseline PMN migration and PMN chemotaxis towards IL-8 and fMLP. We also show that this effect is suppressed by an anti-RAGE monoclonal antibody and that AGEs also induce a decrease in PMN migration. These data are in keeping with a report from Touré et al. [22] , who found that AGEcollagen inhibited PMN chemotaxis in response to chemoattractants. HMGB1 release by dying cells at inflammatory sites, including PMN [23] , could trigger a different 'braking circuit' that limits neutrophil recruitment and thereby reduces collateral tissue damage during physiological inflammatory responses. Thus, our study identifies HMGB1 as one of few molecules, alongside lactoferrin, lipoxins, netrin-1 and annexin-1, that negatively regulate neutrophil migration [24] [25] [26] [27] . This modulation could be attributed to the truncated A box of the protein, In contrast, PMN chemotaxis was enhanced by elevated HMGB1 concentrations (5,000 ng/ml). High HMGB1 concentrations have been found in tissues during chronic inflammatory disorders such as rheumatoid arthritis and cystis fibrosis [28, 29] and might thus amplify PMN recruitment to the inflammatory site and lead to bystander tissue damage. In keeping with the results of structure-function studies [7] demonstrating that the active cytokine domain of HMGB1 is located in the DNA-binding B box, we found that the B box, when used alone, increased PMN migration and modulated CD11b and L -selectin expression at the PMN surface. The observed chemotactic effect of HMGB1 involved blood-cell production of IL-8, which exerts its chemoattractant function even at concentrations as low as 2.5 ng/ ml. In contrast, the stimulatory effect of IL-8 on ROS production and PMN survival (online supplementary figure 1, www.karger.com/doi/10.1159/000328798) in whole-blood conditions appears at higher concentrations (above 25 ng/ml), explaining, at least in part, why and TLR4 in HMGB1-induced IL-8 production. Whole-blood samples were pretreated for 30 min with blocking anti-RAGE antibody (10 g/ml), blocking anti-TLR2 antibody (10 g/ml), or blocking anti-TLR4 antibody (10 g/ml) and then incubated for 3 h with PBS or HMGB1 (5,000 ng/ml). IL-8 production was measured as described above. Values are means 8 SEM (n = 3). * Significantly different from samples incubated with HMGB1 alone (p ! 0.05).
the B box did not stimulate these functions. In addition, the chemoattractant effect of HMGB1 was countered by pretreatment with anti-TLR2 and anti-TLR4 antibodies, in keeping with the involvement of TLR2 and TLR4 in HMGB1-induced IL-8 production. Finally, the synergistic effect of fMLP and HMGB1 (5,000 ng/ml) may be related to cross talk between TLR4 and chemokine receptors, leading to a marked increase in chemokinedriven migration [31] .
The intracellular signaling pathways mediating the biological effects of extracellular HMGB1 are poorly documented. In particular, although RAGE has been identified as the receptor for HMGB1, we do not know how RAGE transfers signals to the effectors required for cytoskeleton remodeling and cell migration to the transcriptional machinery. HMGB1 binding to RAGE leads to the activation of multiple signaling molecules, including ERK1/2, p38MAPK, the small GTPases rac and Cdc42, Transduction pathways involved in HMGB1 modulation of PMN migration. a , b Involvement of RAGE, TLR2 and TLR4 in HMGB1-induced modulation of PMN migration. a Before being applied to the upper chambers, whole-blood samples were pretreated at room temperature for 30 min with blocking anti-RAGE antibody (10 g/ml), blocking anti-TLR2 antibody (10 g/ml), or blocking anti-TLR4 antibody (10 g/ml). The lower well of each chamber received 600 l of PBS-HSA or HMGB1 (100 ng/ml or 5,000 ng/ml). The chambers were incubated for 1 h (HMGB1 100 ng/ml) or 3 h (HMGB1 5,000 ng/ml) at 37 ° C. The results are expressed as the percentage inhibition or percentage increase, depending on the HMGB1 concentration (100 or 5,000 ng/ml, respectively) as de- 
